Inactivated pandemic 2009 H1N1 influenza A virus human vaccines have different efficacy after homologous challenge in the ferret model.
adjuvant
efficacy
ferret
immunopathology
influenza A
pandemic 2009 H1N1
vaccine
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
10
12
2019
revised:
06
05
2020
accepted:
21
06
2020
pubmed:
12
8
2020
medline:
26
11
2021
entrez:
12
8
2020
Statut:
ppublish
Résumé
The 2009 pandemic H1N1 (A(H1N1)pdm09) influenza A virus (IAV) has replaced the previous seasonal H1N1 strain in humans and continues to circulate worldwide. The comparative performance of inactivated A(H1N1)pdm09 influenza vaccines remains of considerable interest. The objective of this study was to evaluate the efficacy of two licensed A(H1N1)pdm09 inactivated vaccines (AS03B adjuvanted split virion Pandemrix from GlaxoSmithKline and referred here as (V1) and non-adjuvanted whole virion Celvapan from Baxter and referred here as (V2)) in ferrets as a pre-clinical model for human disease intervention. Naïve ferrets were divided into two groups (V1 and V2) and immunised intramuscularly with two different A/California/07/2009-derived inactivated vaccines, V1 administered in a single dose and V2 administered in 2 doses separated by 21 days. Six weeks after the first immunisation, vaccinated animals and a non-vaccinated control (NVC) group were intra-nasally challenged with 10 Results revealed important qualitative differences in the performance of both inactivated vaccines in relation to protection against challenge with a comparable virus in a naive animal (ferret) model of human disease. Vaccine V1 limited and controlled viral shedding and reduced lower respiratory tract infection. In contrast, vaccine V2 did not control infection and animals showed sustained viral shedding and delayed lower respiratory infection, resulting in pulmonary lesions, suggesting lower efficacy of V2 vaccine.
Sections du résumé
BACKGROUND
The 2009 pandemic H1N1 (A(H1N1)pdm09) influenza A virus (IAV) has replaced the previous seasonal H1N1 strain in humans and continues to circulate worldwide. The comparative performance of inactivated A(H1N1)pdm09 influenza vaccines remains of considerable interest. The objective of this study was to evaluate the efficacy of two licensed A(H1N1)pdm09 inactivated vaccines (AS03B adjuvanted split virion Pandemrix from GlaxoSmithKline and referred here as (V1) and non-adjuvanted whole virion Celvapan from Baxter and referred here as (V2)) in ferrets as a pre-clinical model for human disease intervention.
METHODS
Naïve ferrets were divided into two groups (V1 and V2) and immunised intramuscularly with two different A/California/07/2009-derived inactivated vaccines, V1 administered in a single dose and V2 administered in 2 doses separated by 21 days. Six weeks after the first immunisation, vaccinated animals and a non-vaccinated control (NVC) group were intra-nasally challenged with 10
RESULTS AND CONCLUSIONS
Results revealed important qualitative differences in the performance of both inactivated vaccines in relation to protection against challenge with a comparable virus in a naive animal (ferret) model of human disease. Vaccine V1 limited and controlled viral shedding and reduced lower respiratory tract infection. In contrast, vaccine V2 did not control infection and animals showed sustained viral shedding and delayed lower respiratory infection, resulting in pulmonary lesions, suggesting lower efficacy of V2 vaccine.
Identifiants
pubmed: 32779850
doi: 10.1111/irv.12784
pmc: PMC7767958
doi:
Substances chimiques
Adjuvants, Immunologic
0
Antibodies, Viral
0
Influenza Vaccines
0
Vaccines, Inactivated
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
142-153Informations de copyright
© 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Références
Influenza Other Respir Viruses. 2013 May;7(3):393-402
pubmed: 22716314
PLoS One. 2012;7(3):e33180
pubmed: 22438897
Vet Res. 2014;45:85
pubmed: 25163545
Vet Res. 2016 Nov 8;47(1):113
pubmed: 27825367
Clin Vaccine Immunol. 2012 Jul;19(7):1012-8
pubmed: 22573737
Vaccine. 2011 Mar 3;29(11):2120-6
pubmed: 21238573
BMJ. 2010 May 27;340:c2649
pubmed: 20508026
Influenza Other Respir Viruses. 2021 Jan;15(1):142-153
pubmed: 32779850
Br Med Bull. 1979 Jan;35(1):69-75
pubmed: 367490
Pediatr Infect Dis J. 2015 Jul;34(7):774-82
pubmed: 26069949
Vaccine. 2014 Sep 29;32(43):5730-9
pubmed: 25173481
Public Health Genomics. 2013;16(1-2):9-16
pubmed: 23548712
Vaccine. 2019 Jul 9;37(30):4015-4021
pubmed: 31201055
Vaccine. 2017 Apr 11;35(16):1996-2006
pubmed: 28302409
PLoS Med. 2010 Apr 06;7(4):e1000258
pubmed: 20386731
J Virol. 2011 Mar;85(6):2851-8
pubmed: 21209108
PLoS One. 2010 Dec 09;5(12):e14270
pubmed: 21151563
Lancet Infect Dis. 2014 Jan;14(1):57-69
pubmed: 24239327
Influenza Other Respir Viruses. 2010 Sep;4(5):277-93
pubmed: 20716157
J Clin Microbiol. 2002 Sep;40(9):3256-60
pubmed: 12202562
J Virol. 2012 Jan;86(1):11-8
pubmed: 22013031
PLoS One. 2012;7(8):e42343
pubmed: 22905124
Curr Top Microbiol Immunol. 2009;333:323-44
pubmed: 19768413
Clin Vaccine Immunol. 2010 Dec;17(12):1829-35
pubmed: 20876821
Dev Biol (Basel). 2003;115:63-73
pubmed: 15088777